Dr. Susan Mcdonald, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 100 Walco Ln, Malvern, AR 72104 Phone: 501-337-8082 |
Dr. Cody Paul Sanders, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 927 S Main St, Malvern, AR 72104 Phone: 501-625-2717 |
Jessica L Teale, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 937 S Main St, Malvern, AR 72104 Phone: 501-337-9559 |
William R Voss, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 206 E Highland Ave, Malvern, AR 72104 Phone: 501-337-7422 Fax: 501-337-9044 |
Dr. Lisa Lynn Loftis, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 306 S Ash St, Malvern, AR 72104 Phone: 501-332-4979 Fax: 501-337-7097 |
Dr. Clyde S Efird, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 927 S Main St, Malvern, AR 72104 Phone: 501-337-9559 Fax: 501-337-7447 |
Madison M Taliaferro, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 372 Coral Rd, Malvern, AR 72104 Phone: 501-337-9212 Fax: 501-337-0280 |
Dr. Michael Lindsey Kinard, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 927 S Main St, Malvern, AR 72104 Phone: 501-337-9559 Fax: 501-337-7447 |
David L Brewer, DDS Dentist Medicare: Medicare Enrolled Practice Location: 230 Pine Bluff St, Malvern, AR 72104 Phone: 501-337-4908 Fax: 501-337-9929 |
News Archive
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR).
Serotonin is a major signaling chemical in the brain, and it has long been thought to be involved in aggressive behavior in a wide variety of animals as well as in humans.
Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.
Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.
› Verified 3 days ago